Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 8, 2005, Pages 4888-4894

  Mari, A ^a   Sallas, W M ^b   He, Y L ^c   Watson, C ^c   Ligueros Saylan, M ^b   Dunning, B E ^d   Deacon, C F ^e   Holst, J J ^e   Foley, J E ^b  

^a Institute of Biomedical Engineering   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d PharmaWrite LLC   (United States)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; PLACEBO; VILDAGLIPTIN;

ADULT; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MALE; MATHEMATICAL MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADAMANTANE; ADENOSINE DEAMINASE; ADULT; ANTIGENS, CD26; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FEMALE; GLYCOPROTEINS; HUMANS; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; TREATMENT OUTCOME;

EID: 23844463766     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2004-2460     Document Type: Article

References (42)

1. Holst JJ, Deacon CF 1998 Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47:1663-1670
2. Kreymann B, Williams G, Ghatei MA, Bloom SR 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304
3. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tahiro F, Miyazaki J, Seino Y 1999 Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96:14843-14847
4. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ 1996 Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2:1254-1258
5. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA 1996 Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 19:580-586
6. D'Alessio DA, Prigeon RL, Ensinck JW 1995 Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes 44:1433-1437
7. Prigeon RL, Quddusi S, Paty B, D'Alessio DA 2003 Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol 285:E701-E707
8. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, Hellstrom PM 1999 GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 277:R910-R916
9. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C 1999 Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541-R1544
10. Zander M, Madsbad S, Madsen JL, Holst JJ 2002 Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
11. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R 2002 Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397-4408
12. Dardik B, Valentin M, Schwarztkopf C, Gutierrez C, Stevens D, Russel M, Villhauer E, Hughes T 2003 NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant cynomolgus monkeys. Diabetes 52(Suppl 1):A322
13. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE 2003 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]- 2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46:2774-2789
14. Ahren B, Landin-Olsson M, Jansson P-A, Svenson M, Holmes D, Schweizer A 2004 Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084
15. Ahren B, Holst JJ, Martensson H, Balkan B 2000 Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 404:239-245
16. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X 1999 Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331
17. Mitani H, Takimoto M, Kimura M 2002 Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity. Jpn J Pharmacol 88:451-458
18. Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson PA, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D 2002 Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25:869-875
19. van Cauter E, Mestrez F, Sturis J, Polonsky KS 1992 Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368-377
20. Mari A, Tura A, Gastaldelli A, Ferrannini E 2002 Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 51(Suppl 1):S221-S226
21. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E 2002 Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. Am J Physiol 283:E1159-E1166
22. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ 2000 Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575-3581
23. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ 2001 A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 24:539-548
24. Ritzel R, Orskov C, Holst JJ, Nauck MA 1995 Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38:720-725
25. Ahren B, Holst JJ, Mari A 2003 Characterization of GLP-1 effects on β-cell function after meal ingestion in humans. Diabetes Care 26:2860-2864
26. Kjems LL, Holst JJ, Volund A, Madsbad S 2003 The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380-386
27. Mentlein R 1999 Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept 85:9-24
28. Larsen MO, Rolin B, Ribel U, Ribel U, Wilken M, Deacon CF, Svendsen O, Gotfredsen CF, Carr RD 2003 Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced β-cell mass. Exp Diabesity Res 4:93-105
29. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ 2002 Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172:355-362
30. Lambeir A-M, Durinx C, Proost P, Van Damme J, Scharpe S, De Meester I 2001 Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett 507:327-330
31. Deacon CF, Ahren B, Holst JJ 2004 Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Invest Drugs 13:1091-1102
32. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ 2004 Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53:1326-1335
33. Ahren B, Larsson H, Holst JJ 1997 Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478
34. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
35. Vilsboll T, Krarup T, Madsbad S, Holst JJ 2002 Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45:1111-1119
36. Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, Nauck MA 2003 Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46:798-801
37. Boden G, Ruiz J, Kim CJ, Chen X 1996 Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects. Am J Physiol 270:E251-E258
38. Boden G 1997 Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10
39. Rossetti L, Giaccari A, DeFronzo RA 1990 Glucose toxicity. Diabetes Care 13:610-630
40. Buteau J, El Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M 2004 Glucagon-like peptide-1 prevents β cell glucolipotoxicity. Diabetologia 47:806-815
41. Egan JM, Meneilly GS, Habener JF, Elahi D 2002 Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 87:3768-3773
42. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Finegood DT, Elahi D 2001 Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24:1951-1956